- Pagina principale
- Analisi delle app
- AnticoagEvaluator
- AnticoagEvaluator Vs. MAQI2 Anticoagulation Toolkit
AnticoagEvaluator vs. MAQI2 Anticoagulation Toolkit Utilizzo e statistiche
Make well-informed decisions on antithrombotic therapy for your non-valvular AF patients with the updated AnticoagEvaluator.
Use the app to:
• Calculate a patient's renal function and risk of ischemic stroke, thromboembolism, and bleed
• Review ACC/AHA/HRS Guideline-driven therapy guidance for stroke prevention
• Generate individualized risk for antithrombotic therapy options based on individual clinical trials.
• Improve accurate use of DOACs with adjusted dosage based on prescribing information, fine-tuned for renal and other patient characteristics.
This app is based on SPARC Tool, developed by Peter Loewen, ACPR, Pharm.D., FCSHP, which can be viewed at www.sparctool.com
- App Store di Apple
- Gratis
- Settore Medico
Classifica degli store
- -
This mobile app provides healthcare practitioners with an up-to-date, easy-to-use resource for managing anticoagulation patients more safely and effectively. The content was developed by the Michigan Anticoagulation Quality Improvement Initiative (MAQI2), a Blue Cross Blue Shield/Blue Care Network of Michigan sponsored consortium of anticoagulation clinics and experts from across the state of Michigan, and is based on the latest guidelines and research.
- App Store di Apple
- Gratis
- Settore Medico
Classifica degli store
- -
AnticoagEvaluatorRanking a confronto con MAQI2 Anticoagulation Toolkit
Confronta la tendenza di classifica AnticoagEvaluator nei ultimi 28 giorni rispetto a MAQI2 Anticoagulation Toolkit
Rank
Nessun dato disponibile
Classifica AnticoagEvaluator vs. MAQI2 Anticoagulation Toolkit per paese a confronto
Confronta la tendenza di classifica AnticoagEvaluator nei ultimi 28 giorni rispetto a MAQI2 Anticoagulation Toolkit
Nessun dato da visualizzare
Fai confronti con qualsiasi sito con la nostra prova gratuita
AnticoagEvaluator VS.
MAQI2 Anticoagulation Toolkit
19icembre d, 2024